Conventional Therapy in Adult Acute Lymphoblastic Leukemia: Review of the LALA Program

Thomas, Xavier; Fière, D

doi:10.1007/978-3-540-72304-2_11

Cited by 2 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48 Subtype-specific, risk-adapted and targeted therapy designs have become major objectives of more recent clinical trials. [49][50][51][52] Table 3 summarizes established multiple-drug ALL regimens.…”

Section: Therapy Of Frontline Acute Lymphoblastic Leukemiamentioning

confidence: 99%

Adult acute lymphoblastic leukemia

Faderl

O’Brien

Pui

et al. 2010

Cancer

230

164

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL.

show abstract

Section: Therapy Of Frontline Acute Lymphoblastic Leukemiamentioning

confidence: 99%

Adult acute lymphoblastic leukemia

Faderl

O’Brien

Pui

et al. 2010

Cancer

230

164

View full text Add to dashboard Cite

show abstract

Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Saltman

Barlev

Seshagiri³

et al. 2015

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe prognosis for adult patients with Ph(-) B-precursor acute lymphoblastic leukaemia (ALL) who are refractory to treatment or experience relapse (R/R), is poor; over 90 % of these patients die from the disease, typically within a few months. While there are some national guidelines published for the treatment of adult patients with ALL, and local working group recommendations do exist, there is very little detail and no preferred treatment regimens for adult patients with R/R Ph(-) B-precursor ALL. The aim of this study was to describe current real-world clinical practice in Europe for the management and treatment of adult R/R Ph(–) B-precursor ALL.MethodsA web-based, double-blind survey was conducted in November/December 2013 in France, Germany, Italy, Spain, and the UK. The survey was developed following consultation with specialist clinicians and a critical review of published literature. Eligible clinicians (15 per country) were board-certified in haemato-oncology or haematology; had at least 4 years of experience in their current role and had treated at least five patients with adult ALL in the 36 months before the survey, including at least one with R/R Ph(−) B-precursor ALL.ResultsClinicians across the five countries consulted 16 guidelines and local working group recommendations for the diagnosis and treatment of R/R Ph(–) B-precursor ALL. Thirty three regimens for salvage therapy were reported; the most frequently cited was augmented hyper-CVAD (15 %), with vincristine the most commonly used agent. Salvage therapy regimens involved a range of agents, and most respondents reported using at least one cytotoxic agent; across respondents 10 different cytotoxic agents were cited. All respondents reported that toxicity was common for the regimens they used to treat R/R Ph(–) B-precursor ALL.ConclusionsThis study provides evidence of current management and treatment patterns of R/R Ph(–) B-precursor ALL in the real-world clinical practice in Europe. The approach to the treatment of R/R Ph(–) B-precursor ALL is heterogeneous, reflecting the lack of any clearly superior chemotherapeutic option, thus it appears that clinicians are trying a wide variety of therapies. These findings show a clear need for effective, tolerable treatments for R/R Ph(–) B-precursor ALL.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1745-4) contains supplementary material, which is available to authorized users.

show abstract

Conventional Therapy in Adult Acute Lymphoblastic Leukemia: Review of the LALA Program

Cited by 2 publications

References 59 publications

Adult acute lymphoblastic leukemia

Adult acute lymphoblastic leukemia

Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Contact Info

Product

Resources

About